Diphenylarsinic acid (DPAA) was detected as the primary compound responsible for the arsenic poisoning that occurred in Kamisu, Ibaraki, Japan, where people using water from a well that was contaminated with a high level of arsenic developed neurological (mostly cerebellar) symptoms and dysregulation of regional cerebral blood flow. To understand the underlying molecular mechanism of DPAA-induced cerebellar symptoms, we focused on astrocytes, which have a brain-protective function. Incubation with 10 mM DPAA for 96 h promoted cell proliferation, increased the expression of antioxidative stress proteins (heme oxygenase-1 and heat shock protein 70), and induced the release of cytokines (MCP-1, adrenomedullin, FGF2, CXCL1, and IL-6). Furthermore, DPAA overpoweringly increased the phosphorylation of three major mitogenactivated protein kinases (MAPKs) (ERK1/2, p38MAPK, and SAPK/JNK), which indicated MAPK activation, and subsequently induced expression and/or phosphorylation of transcription factors (Nrf2, CREB, c-Jun, and c-Fos) in cultured rat cerebellar astrocytes. Structure-activity relationship analyses of DPAA and other related pentavalent organic arsenicals revealed that DPAA at 10 mM activated astrocytes most effective among organic arsenicals tested at the same dose. These results suggest that in a cerebellum exposed to DPAA, abnormal activation of the MAPK-transcription factor pathway and irregular secretion of these neuroactive, glioactive, and/or vasoactive cytokines in astrocytes can be the direct/indirect cause of functional abnormalities in surrounding neurons, glial cells, and vascular cells: This in turn might lead to the onset of cerebellar symptoms and disruption of cerebral blood flow.
An arsenic poisoning incident occurred in Kamisu, Ibaraki, Japan in 2003; arsenic chemicals at 4.5 mgAs/l concentration were detected in the well water, of which diphenylarsinic acid (DPAA) was the main compound. Further investigation revealed that the well water had been contaminated with arsenic chemicals leaked from a concrete block buried near the well. People using this water for domestic purposes suffered from neurological symptoms suggestive of cerebellar dysfunction, including vertigo and coordination problems, myoclonus, somnipathy, visual disorders, and recent memory and cognitive disturbances (Ishii et al., 2004) , which were believed to be caused by DPAA. DPAA is not a natural product and could be a raw material or degradation product of chemical weapons, such as diphenylcyanoarsine and diphenylchloroarsine, which can cause severe vomiting and sneezing. To date, however, no historical evidence of the production or storage of these chemical weapons at Kamisu has been reported. Thus, the exact source of the DPAA remains unclear. Some victims had recovered after stopping the use of the contaminated well water, some had been afflicted with cerebellar symptoms for a long time, and several children born during the poisoning suffered from developmental disorders (Ishii et al., 2004) .
Several studies have examined the toxicity of DPAA in mammals in vitro and in vivo; DPAA-induced oxidative stress in rat cerebellar Purkinje cells (Kato et al., 2007) , downregulation of glutaminase C (Kita et al., 2007) , and promotion of glutaminase C degradation by the mitochondrial Lon protease (Kita et al., 2012) in HepG2 cells.
However, precise molecular mechanisms of DPAA-induced cerebellar symptoms remain largely unknown. We have previously reported that primary cultured cerebellar cells were vulnerable to DPAA and that in rat cerebellar astrocytes but not in neurons, DPAA at 10 mM induced a marked increase in the expression of cytoprotective proteins, heme oxygenase-1 (HO-1) and an inducible oxidative stress-related protein, heat shock protein 70 (Hsp70), which provide defense against oxidative stress, as well as in the release of neuroactive and vasoactive peptides, such as MCP-1 (CCL2), CXCL1, adrenomedullin (ADM), and FGF-2 (Negishi et al., 2012) , which suggests activation of astrocytes by DPAA. Furthermore, we have demonstrated that developmental subchronic exposure to DPAA in rats in vivo induced abnormal behavioral development (increased exploratory behavior and impaired learning behavior) and decreased cerebellar glutathione levels (Negishi et al., 2013) .
In the present study, we investigated the biological mechanisms underlying DPAA-induced astrocyte activation with the goal of identifying potential therapeutic or prophylactic agents against the intoxication of DPAA. We first evaluated the cytotoxicity of DPAA in cultured rat cerebellar astrocytes and confirmed DPAA-induced astrocyte activation, including morphological changes, promotion of cell proliferation, increased expression of antioxidative stress proteins, and releases of cytokines, such as MCP-1, ADM, FGF-2, CXCL1, and IL-6. We then showed that DPAA induced remarkable activation of the mitogen-activated protein kinases (MAPKs), such as ERK1/2, p38MAPK, and SAPK/JNK, which have pivotal roles in cell proliferation, growth, survival, and cell death, and that, subsequently, DPAA induced expression and/or phosphorylation of transcription factors, such as Nrf2, cAMP response element-binding protein (CREB), c-Jun, and c-Fos. In addition, we performed structure-activity relationship analysis of DPAA and related organic arsenicals, including the compounds detected in the accident and expected metabolites of DPAA in the human body; phenylarsonic acid (PAA), phenylmethylarsinic acid (PMAA), phenyldimethylarsine oxide (PDMAO), and diphenylmethylarsine oxide (DPMAO) (Ishizaki et al., 2005; Kita et al., 2009) , to elucidate any structure responsible for the biological effects of DPAA. The analysis clearly showed that DPAA was the most active among the pentavalent organic arsenicals tested. We noted here that DPAA itself is neither a chemical warfare agent nor a compound causing nausea and vomiting, but a raw material or degradation product, biological influence of which on human health was largely unknown, and thus we investigated adverse effects of DPAA for better understanding a biological and toxicological significance in the Kamisu accident.
MATERIALS AND METHODS
Chemicals. DPAA was provided by Tri Chemical Laboratories (Yamanashi, Japan). Purity of DPAA was more than 99%. PAA and DPMAO were purchased from Hayashi Pure Chemical (Osaka, Japan), and PMAA and PDMAO were purchased from Wako Pure Chemical (Osaka, Japan).
Animals. Pregnant Wistar rats were purchased from Japan SLC (Shizuoka, Japan) and maintained under controlled temperature (24 6 1 C) and humidity (55 6 5%) on a 12-h light/12-h dark cycle.
All animal experiments were approved by the Animal Experimentation Committee of Aoyama Gakuin University and performed under veterinary supervision.
Cell culture. Cerebellar cells from neonatal Wistar rats at postnatal day 2 were primarily cultured as previously described (Negishi et al., 2012) . Briefly, under sterile conditions, dissected cerebella were dispersed by 0.5% trypsin-EDTA (Invitrogen, Carlsbad, California). Cells were plated at 100 cells/mm 2 in DMEM/F12 (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) for 7-10 days, when proliferative astrocytes were dominant in the culture dish. Astrocytes were subsequently passaged using trypsin and plated at 100 cells/mm 2 . After 5-6 passages, sufficient numbers of astrocyte were frozen and preserved in liquid nitrogen until use. All experiments in the present study were performed by using cultured astrocytes that had experienced 7-9 passages.
Cell viability. Cell viability of cultured astrocytes exposed to DPAA or other chemicals was quantified using a CellTiter-Blue Cell Viability Assay (Promega) and CellTiter-Glo 2.0 Assay (Promega).
Cytotoxicity. The cytotoxicities of DPAA and other chemicals were measured using a CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega), which quantifies lactose dehydrogenase (LDH) released from dead cells.
Live/dead cell staining. Cells exposed to DPAA or other chemicals were incubated simultaneously with propidium iodide (PI; Sigma-Aldrich), a membrane impermeable dye, at 0.67 mg/ml and Hoechst 33342 (Sigma-Aldrich), a membrane permeable dye, at 0.67 mg/ml. Consequently, live cell nuclei were stained only with Hoechst, whereas dead cell nuclei, the membrane integrity of which was corrupt, were stained with both Hoechst and PI. The number of PI-positive nuclei was considered to be that of dead cells, and the difference between the number of Hoechst-positive and PI-positive nuclei was considered to be that of living cells. Western blotting. The expression level or phosphorylation level of protein in cultured astrocytes was evaluated by Western blotting.
NEGISHI ET AL. | 75
Sample preparation and Western blotting were performed according to our previous report (Negishi et al., 2012 Enzyme-Linked Immunosorbent Assay. Enzyme-Linked Immunosorbent Assay (ELISA) kits for each peptide were as follows: MCP-1 (CCL2) EIA Kit (Immuno-Biological Laboratories, Gunma, Japan) for MCP-1 (CCL2); adrenomedullin (1-50) (rat), EIA Kit (Phoenix Pharmaceuticals) for ADM; human FGF basic Quantikine ELISA Kit (R&D Systems); Cxcl1 (Rat) ELISA Kit (Abnova, Taipei City, Taiwan) for CXCL1; and Rat IL-6 Quantikine ELISA Kit for IL-6 (R&D Systems). The culture medium after exposure to DPAA or other compounds were subjected to ELISA directly or after concentration by vacuum centrifugation. ELISA was performed according to the product manual.
Statistical analyses. The cell viability or cytotoxicity of DPAA or other compounds (Figs. 1 and 5) was analyzed by one-way analysis of variance (ANOVA), which was followed by Dunnett's multiple comparisons versus control value. The concentration of peptides released from astrocytes exposed to DPAA at 10 mM for 96 h (Figure 2 ), which consisted of only two groups, was analyzed by using Student's t test. The numerical values of relative protein expression (Figs. 4 and 5) and concentrations of peptides released from astrocytes exposed to DPAA or other compounds ( Figure 5 ) were analyzed by one-way ANOVA followed by Dunnett's tests.
RESULTS

Cytotoxicity of DPAA in Cultured Astrocytes
In the present study, cultured rat cerebellar astrocytes were prepared from primary rat cerebellar cells cultured in serum-containing medium. Cultured cells were passaged 5-6 times, and astrocytes having high proliferative activity were subsequently selected and purified. DPAA ( Figure 1A ) at 10 mM dramatically affected the shape of cultured astrocytes after 96 h exposure ( Figure 1B ). Cultured astrocytes in the control medium had showed a flat shape and covered the culture dish; however, those exposed to DPAA had a rounded shape. In the present study, four types of assays were used to investigate cytotoxicity of DPAA: an oxidoreductase-based cell viability assay (CellTiter-Blue assay), an ATP-based cell viability assay (CellTiter-Glo), an LDH-released cytotoxicity assay (CytoTox-ONE), and a membrane permeability-based nuclei visualization assay. Although DPAA decreased cell oxidoreductasebased cell viability at 50 mM, DPAA at 3.13-12.5 mM significantly (P < 0.05) increased oxidoreductase activity, ie, cell viability ( Figure 1C ). In the ATP-based cell viability assay ( Figure 1D ), DPAA at 25 and 50 mM significantly (P < 0.05) decreased cell viability. On the other hand, DPAA at 12.5-50 mM significantly (P < 0.05) increased LDH release in the culture medium, which meant DPAA-induced cell death ( Figure 1E ). Furthermore, live/ dead staining using a membrane permeable dye (Hoechst33342) and an impermeable dye (PI) indicated that DPAA at 6.25 and 12.5 mM significantly (P < 0.05) increased the number of live cells and DPAA at 25 and 50 mM significantly (P < 0.05) decreased the number of live cells; simultaneously, DPAA at 25 and 50 mM significantly (P < 0.05) increased the number of dead cells ( Figure 1F ). In addition, DPAA at 6.25 mM DPAA marginally (P ¼ 0.07) and 12.5 mM or higher significantly (P < 0.05) increased the number of total cells (the sum of live and dead cells: Hoechst33342-positive nuclei) (457 6 48 at 0 mM, 504 6 39 at 6.25 mM, 536 6 63 at 12.5 mM, 518 6 65 at 25 mM, and 636 6 780 at 50 mM [mean 6 SD]) (also see Figure 1F ). On the whole, the LD 50 of DPAA was estimated to be approximately 50 mM, and exposure to DPAA at least at 10 mM for 96 h induced no apparent cell death and it slightly but significantly stimulated cell proliferation in cultured astrocytes. As for the balance between DPAA-induced cell proliferation and death, proliferation was dominant at approximately 10 mM, while death was dominant at 25 and 50 mM, which might explain the reduction in the number of live cells by higher doses of DPAA.
DPAA-Induced Increased Expression of Antioxidative Stress Proteins and Release of Cytokines in Cultured Astrocytes
In our previous study (Negishi et al., 2012) , exposure to DPAA in primary cultured rat cerebellar cells in vitro and adult rats in vivo increased expression of the cytoprotective proteins, HO-1 and inducible Hsp70, which were well-known antioxidative stress proteins. As expected, in cultured rat astrocytes, DPAA at 10 mM induced protein expression of HO-1 and Hsp70 after 24 and 48 h, respectively (Figure 2A) , and little affected protein expression of GFAP, an astrocyte marker. Furthermore, DPAA at 10 mM induced significant increases in the release of MCP-1, ADM, and FGF2 ( Figure 2B ) in cultured rat astrocytes, which had been identified in primary cultured rat cerebellar cells in our previous study (Negishi et al., 2012) . In addition, comprehensive analyses of DPAA-induced alteration in gene expression in primary cultured rat cerebellar cells implied a significant increase in CXCL1 expression (Negishi et al., 2012) , and cytokine array of the culture medium, from astrocytes cultured in DPAA-containing medium to identify DPAA-sensitive cytokine(s), implied induction of IL-6 release by DPAA (data not shown). In the present study, DPAA at 10 mM induced significant (P < 0.05) increases in the release of CXCL1 and IL-6 in cultured astrocytes ( Figure 2B ).
Late-Onset Activation of MAPKs and Induction/Activation of Transcription Factors by Exposure to DPAA in Cultured Astrocytes
To explore the biological effects of DPAA in cultured astrocytes activated by DPAA, Western blot analyses for 3 well-known MAPKs; ERK1/2, p38MAPK, and SAPK/JNK, were performed. DPAA at 10 mM induced phosphorylation of ERK1/2, p38MAPK, and SAPK/JNK ( Figure 3A ). In addition, DPAA at 10 mM induced phosphorylation of CREB ( Figure 3B ), although it seemed to induce a slight reduction in total CREB protein expression. On the other hand, DPAA induced both protein expression and phosphorylation of c-Jun and c-Fos ( Figure 3B ).
Time-and Dose-Dependent Effects of DPAA in Cultured Rat Astrocytes Because we found that DPAA at 10 mM activated rat cerebellar astrocytes in a late-onset manner, the dose dependencies (0.016, 0.08, 0.4, 2, and 10 mM) and time courses (96 and 336 h) of DPAA-induced adverse effects were assessed. It should be noted that DPAA at 10 mM induced severe cell death after 336 h (data not shown). Thus, the data of this point were excluded for quantification and indicated as "NA" (Figs. 4B, 4D , and 4 F). DPAA had no significant effect on GFAP, except that at 2 mM, the expression significantly (P < 0.05) decreased after 336 h (Figs. 4A and  4B ). DPAA at 10 mM induced a significant (P < 0.05) increase in protein expression of not only HO-1 and Hsp70 but also of Nrf2 (Figs. 4A and 4B ), which is a well-known transcription factor for HO-1, after 96-h exposure. However, exposure to DPAA at 10 mM for 336 h led to such severe cell death of cultured astrocytes that protein expressions of HO-1, Hsp70, and Nrf2 could not be detected. DPAA at 2 mM also induced a significant (P < 0.05) increase in protein expression of HO-1 after 96-h exposure and even after 336-h exposure (Figs. 4A and 4B ). DPAA at 10 mM induced significant (P < 0.05) activation (phosphorylation) of ERK1/2, p38MAPK, and SAPK/JNK after 96-h exposure (Figs. 4C and 4D), and induced significant (P < 0.05) reduction in total ERK1/2 expression. DPAA at 2 mM induced significant (P < 0.05) increases in phosphorylation of ERK1/2 and p38MAPK but not of SAPK/JNK after 96-h exposure. In addition, DPAA at 2 mM induced a significant (P < 0.05) increase in phosphorylation of ERK1/2 and significant (P < 0.05) decreases in total protein expressions of ERK1/2, p38MAPK, and SAPK/JNK after 336-h exposure (Figs. 4C and 4D ). DPAA at 10 mM subsequently induced significant (P < 0.05) increases in phosphorylation of the transcription factors CREB, c-Jun, and c-Fos, a significant (P < 0.05) decrease in protein expression of CREB, and significant (P < 0.05) increases in the protein expressions of c-Jun and c-Fos (Figs. 4E and 4F) after 96-h exposure. DPAA at 2 mM induced significant (P < 0.05) increases in phosphorylation of CREB and protein expression of c-Jun after 96-h exposure and induced a significant (P < 0.05) decrease and increase in the protein expressions of CREB and c-Jun, respectively, after 336-h exposure (Figs. 4E  and 4F ).
Structure-Activity Relationship of DPAA and Related Organic Arsenicals
The organic arsenicals detected in the Kamisu accident and their related metabolites in the human body were PAA, PMAA, PDMAO, and DPMAO in addition to DPAA ( Figure 5A ). The cytotoxicities of these organic arsenicals were assessed using an oxidoreductase-based cell viability assay (CellTiter-Blue assay) ( Figure 5B) . DPAA, as shown earlier, significantly (P < 0.05) increased cell viability based on enzymatic activity at 6.25 and 12.5 mM, whereas DPAA at 50 mM significantly decreased cell viability. PAA at 12.5 and 25 mM significantly (P < 0.05) decreased the cell viability of cultured astrocytes, but PAA at 50 mM had little effect. PMAA significantly (P < 0.05) decreased cell viability at 3.125 and 6.25 mM, had no effect at 12.5 and 25 mM, and again significantly (P < 0.05) decreased cell viability at 50 mM. PDMAO value of the sample exposed to DPAA at 10 lM for 96 h). *P < 0.05 versus 0 mM vehicle control in each exposure time. Note that analysis of the sample exposed to DPAA at 10 lM for 336 h was not analyzed because of severe cell death as indicated in decreased b-actin expression, which was expressed as "NA." shown in (C). E, Western blot analyses of protein expression of phosphorylated or total ERK1/2, p38MAPK, and SAPK/JNK in cultured astrocytes exposed to DPAA and related organic arsenicals at 10 lM for 96 h. F, Densitometric analyses of blots of phosphorylated or total ERK1/2, p38MAPK, and SAPK/JNK shown in (E). G, Western blot analyses of protein expression of phosphorylated or total CREB, c-Jun, and c-Fos in cultured astrocytes exposed to DPAA and related organic arsenicals at 10 lM for as an internal control at the bottom of (C), (E), and (G).
slightly but significantly (P < 0.05) increased the cell viability of astrocytes at 50 mM, the highest dose tested. DPMAO showed no effect on the cell viability of cultured astrocytes. On the whole, it was confirmed that all organic arsenicals tested had little cytotoxicity in cultured astrocytes exposed to the compounds at 10 lM for 96 h, which was why 10 lM was determined to be the dose of compounds used in the following experiments. DPAA induced significant (P < 0.05) increases in the protein expressions of HO-1 and Hsp70, as shown earlier, and PMAA significantly (P < 0.05) increased expression of HO-1 but not of Hsp70 (Figs. 5C and 5D ). On the other hand, PAA, PDMAO, and DPMAO did not affect the protein expressions of HO-1, Hsp70, and Nrf2. When the protein expression and phosphorylation of MAPKs were investigated, only DPAA induced significant (P < 0.05) activation of MAPKs (Figs. 5E and 5F); increased phosphorylation of ERK1/2, p38MAPK, and SAPK/JNK; decreased total protein expression of ERK1/2; and slightly increased expression of SAPK/JNK. PMAA also induced a significant (P < 0.05) increase in the expression of SAPK/JNK. PAA, PDMAO, and DPMAO had little effect on the phosphorylation and expression of MAPKs. DPAA affected transcription factor expression and phosphorylation and induced significant (P < 0.05) increases in the phosphorylation of CREB, c-Jun, and c-Fos and in the protein expression of cJun and c-Fos (Figs. 5G and 5H ). PMAA induced significant (P < 0.05) increases in the phosphorylation of c-Jun and c-Fos and a significant (P < 0.05) increase in protein expression of cJun (Figs. 4G and 4H) . PAA, PDMAO, and DPMAO showed no effect on the phosphorylation and protein expression of transcription factors. Finally, the effects of organic arsenicals on the release of cytokines (MCP-1, ADM, FGF-2, CXCL1, and IL-6) in cultured astrocytes were assessed ( Figure 5I ). DPAA at 10 lM induced significant (P < 0.05) increases in the concentrations of MCP-1, ADM, FGF2, CXCL1, and IL-6. PMAA also induced significant (P < 0.05) increases in the concentrations of MCP-1, FGF2, and IL-6, but it was less potent than was DPAA.
DISCUSSION
In the present study, we demonstrated that DPAA in cultured rat cerebellar astrocytes induced aberrant activation of the MAPKs signaling pathway and released several cytokines capable of affecting neuronal, glial, and/or vascular functions, which might have been responsible for the neurological (cerebellar) symptoms and altered cerebral blood flow in patients exposed to DPAA (Figure 6 ).
In cultured rat cerebellar astrocytes exposed to DPAA for 96 h, the LC 50 of DPAA was approximately 50 mM. Our previous study (Negishi et al., 2012) reported an LD 50 of 30 mM DPAA for 48 h in primary cultured rat cerebellar cells which consisted of a large number of neurons (granule cells). Previous studies reported that the LC 50 values of DPAA were 121 and 700 mM in primary mouse hepatocytes (Sumi et al., 2007) and HepG2 cells (Kita et al., 2009) , respectively. These results meant that neural cells are much more vulnerable to DPAA than are hepatic cells. Interestingly, DPAA at approximately 10 mM significantly increased cell viability determined by oxidoreductase activity, but it had no effect on cellular ATP content. On the other hand, the number-based assay also indicated a slight but significant increase in the number of living cells exposed to DPAA at approximately 10 mM. These results suggest that DPAA at certain dose range (6.25 mM or higher) promotes cell proliferation in cultured astrocytes, although higher doses of DPAA induce cell death simultaneously. No change in ATP content at approximately 10 mM of DPAA might mean that DPAA-activated astrocytes have a smaller amount of ATP per cell compared than do control astrocytes, which implies DPAA-induced ATP depletion in astrocytes.
DPAA induced the protein expression of HO-1 in astrocytes as well as in primary cultured mouse hepatocytes (Sumi et al., 2007) , in primary cultured cerebellar cells in vitro (Negishi et al., 2012) , and in the cerebella of adult rats exposed to DPAA in vivo (Negishi et al., 2013) . In addition, DPAA induced expression of Hsp70 in cultured astrocytes. Induction of these antioxidative stress protein expressions by DPAA exposure suggests generation of reactive oxygen species (ROS) in astrocytes. However, in the present study, induction of HO-1 and Hsp70 commenced 24 and 48 h, respectively, after exposure to DPAA. It is known that trivalent arsenite induces ROS formation rapidly via activation of a specific NADPH oxidase (Ellinsworth, 2015) . In contrast, these late-onset biological responses to DPAA exposure suggest that DPAA might undergo some chemical modification such as reduction and/or conjugation in astrocytes and/or in culture medium, and then the modified DPAA would become a cause of oxidative stress rather than pentavalent intact DPAA directly and rapidly producing ROS. On the other hand, pentavalent inorganic arsenate, a major arsenic in contaminated water, is rapidly reduced to trivalent in blood, which is methylated to pentavalent monomethylarsonic acid, with subsequent reduction/methylation cycles producing trivalent monomethylarsonous, pentavalent dimethylarsinic, and trivalent dimethylarsinous acids (Vahter, 2002; Ellinsworth, 2015) . Although biotransformation of DPAA in the human body largely remains unclear, a previous study using rats revealed that orally administered DPAA was excreted in urine and feces as the original DPAA or in bile as DPAA or glutathione-conjugated DPAA containing trivalent arsenic. Although several mechanisms have been proposed about the causal relationship among arsenicals, ROS, and oxidative stress (Hall et al., 2013) , further investigations to understand the chemical metabolism and behavior of DPAA in vitro and in vivo, especially in the central nervous system (CNS), are important.
We identified five cytokines of which the expression and release could be induced by DPAA in cultured astrocytes; among these, MCP-1, ADM, and FGF2 have been reported in our previous study (Negishi et al., 2012) , and CXCL1 and IL-6 were newly identified in the present study. MCP-1 is an inducible chemokine in astrocytes in response to toxins such as bacterial-associated molecules (McKimmie and Graham, 2010) and methylmercury (Muniroh et al., 2015) . MCP-1 in the brain can interfere with hippocampal synaptic neurotransmission (Nelson et al., 2011) , disrupt the blood-brain barrier (BBB) (Stamatovic et al., 2005) , and protect cortical neurons against excitotoxins (Bruno et al., 2000) . ADM, a potent vasodilatory peptide in circulating blood, can also be synthesized in astrocytes (Serrano et al., 2008; Negishi et al., 2012) , and it has been suggested to participate in the maintenance of resting cerebral blood flow and the BBB (Kis et al., 2003) . Astrocytes are the main source of FGF2, a major growth factor, in the brain (Reuss et al., 1998) , and exert their effect through paracrine and autocrine mechanisms. FGF2 is known to maintain the density of brain blood vessels, promote angiogenesis, and preserve the integrity of the BBB (Bendfeldt et al., 2007) . CXCL1 in the brain is thought to be a key molecule during acute injury or during neurodegeneration (Katayama et al., 2009) and has a critical role in leukocyte recruitment to the brain by controlling endothelial activation (Wu et al., 2015) . IL-6, a well-known proinflammatory cytokine, regulates a large range of biological functions in a variety of tissues including the brain. IL-6 produced mainly in brain astrocytes participates in the response of neurons and glial cells under normal conditions, and in a wide range of injuries in a neurotrophin-like manner (Erta et al., 2012) . Overall, considering the important and versatile functions of these cytokines, cytokines oversynthesized by DPAA exposure might affect neuronal function, alter brain vasculature, and induce inflammation, such as by infiltration of granulocytes, while others may exert competitive actions. In addition, these cytokines may cause neuronal dysfunction, leading to cerebellar symptoms and disrupting blood flow dynamics in CNS in patients in the Kamisu accident.
DPAA-induced cell proliferation, translational upregulation of oxidative stress-related proteins and various cytokines imply involvement of activation of MAPKs, such as ERK1/2, p38MAPK, and SAPK/JNK in these biological consequences. It is well known that almost all types of living cells can use MAPKs in different ways in response to various exogenous/endogenous stimuli including oxidative stress as previously reported (Lu et al., 2011; Senapati et al., 2015) . Interestingly, DPAA induced marked phosphorylation of all the 3 major MAPKs 24 h after DPAA exposure. It is relevant to consider that oxidative stress due to DPAA exposure induced aberrant activation of MAPKs, which might subsequently induce expression of the antioxidative stress protein, HO-1 (Kietzmann et al., 2003) and Hsp70 (Kim et al., 2015) , and synthesis of most of the cytokines mentioned above by activation of MAPK in astrocytes as reported by several groups (FGF2 by ERK1/2 [Kajitani et al., 2015] ; MCP-1 by JNK [Tang et al., 2015] ; IL-6 by ERK1/ 2, p38MAPK, and SAPK/JNK [Fernandes et al., 2007] ; MCP-1, CXCL1, and IL-6 by p38MAPK [Lo et al., 2014] ). Depending on the circumstances, such as cell type, cytokine concentration, and receptor expression, conversely, MAPKs can be activated by extracellular cytokines: p38MAPK activation by MCP-1 (Cho and Gruol, 2008) ; ERK1/2 activation by FGF2 (Delehedde et al., 2000) ; p38MAPK activation by FGF2 (Tan et al., 1996) ; and prevention of ERK1/2 activation by ADM (Armstead et al., 2010) . Thus, it is also possible that these cytokines released from DPAA-exposed astrocytes promoted or prevented activation of MAPKs. Furthermore, it is possible that there are cytokine-cytokine positive or negative feedback loops in DPAA-exposed astrocytes that occur in an autocrine manner as previously reported (Guo et al., 2012; Roy et al., 2012) .
Translational (protein) upregulation of antioxidative stress proteins and brain-active cytokines in response to DPAA interested us in induction of specific transcription factors, CREB, c-Jun, and c-Fos, and their activation, because they were known to be induced under various stresses and to be phosphorylated by MAPKs or downstream kinases activated by MAPKs. As expected, DPAA induced c-Jun and c-Fos protein expression and increased phosphorylation of CREB, c-Jun, and c-Fos. We assumed that DPAA-induced activation of MAPKs causes increase in the expression and activation of transcription factors, which then have pivotal roles in DPAA-induced translational upregulation of antioxidative stress proteins, cytokines, and transcription factors themselves, although further experiments are required to confirm this.
Exposure to DPAA at 10 mM for 96 h dramatically activated MAPK and then induced and/or activated antioxidative stress proteins and transcription factors, which seemed to be quite a severe change. The LD 50 of DPAA for 96 h in cultured astrocytes was approximately 50 mM. However, DPAA at 2 mM exerted only a small adverse effect 96 h and even 336 h after exposure. On the other hand, DPAA at 10 mM induced severe cell death in cultured astrocytes at 336 h after exposure. In the contamination accident, the highest arsenic concentration among the well water samples of Kamisu was 4.5 mgAs/l (Ishizaki et al., 2005) , which corresponds to 15.7 mgDPAA/l or 60 mM DPAA (if all arsenicals were DPAA). Indeed, the predominant form of the arsenic in the well water was DPAA. When male rats were developmentally exposed to DPAA via drinking water (20 mgDPAA/l; 76 mM DPAA) for 6 weeks, cerebellar tissues contained arsenic at 3 mgAs/g, which corresponded to approximately 40 mM DPAA (Negishi et al., 2013) . Although these calculations were rough enough to require caution when extrapolating conclusions to humans, it seemed to be worth elucidating the biological mechanisms of the adverse effects of DPAA at 10 mM to understand the DPAA-induced neurological symptoms of the patients in the accident.
In the structure-activity relationship analyses among DPAA and related organic arsenicals (PAA, PMAA, PDMAO, and DPMAO), the pentavalent arsenicals tested, except for DPMAO, affected the cell viability of astrocytes at a dose range of 3.125-50 mM in different ways. However, only DPAA promoted cell proliferative activity at approximately 10 mM. On the other hand, PAA and PMAA decreased cell viability in a certain dose range, which suggested that these two arsenicals, unlike DPAA, have cytotoxic potency at relatively low doses. Furthermore, in brief, PMAA at 10 mM significantly affected some factors evaluated in a manner similar to that of DPAA, but the intensity of PMAA was far less than that of DPAA at the same dose. The others, PAA, PDMAO, and DPMAO, showed no effect on the factors evaluated. These results suggest that arsine oxides are far less toxic than pentavalent organic arsenic acids and that two alkyl groups covalently bound to arsine appear to be important for toxicity. Based on the present results, DPAA, which has two phenyl groups (diphenyl: DPAA), was more potent than was PMAA, which has a phenyl and a methyl group.
In the present study, we demonstrated that DPAA had severe adverse effects on various aspects of cellular function in astrocytes. Especially, activation of MAPKs seemed to be a key process, which could explain other DPAA-induced biological changes observed reasonably. However, we did not know how DPAA activated three major MAPKs simultaneously. Although ROS induced by DPAA is a promising candidate, we found no direct chemical evidence of ROS production by DPAA in astrocytes, and we had no information about DPAA-attacking molecules leading to ROS production in astrocytes. One possibility is that DPAA reacts with thiol of cysteine residues in ROS-reducing proteins, which results in protein dysfunction and subsequent ROS accumulation. Another possibility is that DPAA reacts with glutathione, an endogenous antioxidant, which results in a shortage of cellular glutathione and subsequent oxidative stress. Another possible explanation of DPAA-induced MAPK activation is that DPAA or ROS may inactivate protein phosphatases that in turn inactivate MAPKs or upstream kinases (Junttila et al., 2008) . Further studies in this area and pharmacological intervention studies using antioxidants, MAP kinase inhibitors, and cytokine receptor antagonists, are critical for understanding the causal relationships between DPAA and the cellular changes described above. Nevertheless, this is the first report demonstrating reactive astrocytes induced by exposure to DPAA at relatively low dose comparable to the accident. We believe that elucidation of the molecular mechanism of DPAA-induced activation of astrocytes will provide the basis for development of preventive and/or therapeutic drugs, especially targeting neurological symptoms, for intoxication caused by DPAA in possible accidents similar to the Kamisu accident.
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